Skip to main content

AngioSoma’s Development of Atherectomy Catheter

Written by Customer Service on . Posted in Public Companies.

Houston, TX, May 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s peripheral arterial disease (“PAD”) product, Atherectomy Catheter II, is a catheter-based platform capable of treating a broad range of plaque types, including calcified plaque and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. This device uses a camera that allows physicians to better control treatment of PAD patients. We have not applied to the United States Food and Drug Administration for clearance to market the Atherectomy Catheter II as a treatment for severely calcified coronary arteries. 
In addition, the Atherectomy Catheter II includes a vacuum mechanism that extracts any removed plaque from the arteries and from the patient.According to estimates by the American Heart Association, as many as 8 to 12 million Americans have PAD. In addition, a study by The SAGE Group, based on the diabetes method, estimated prevalence at 17.6 million in 2010 (The SAGE Group, “The Diabetes Method,” 2011). An aging population, coupled with increasing incidence of diabetes and obesity, is likely to continue to increase the prevalence of PAD. Guidelines from the American College of Cardiology Foundation/American Heart Association in 2011 lowered the recommended age for testing for PAD from 70 to 65, or 50 if the patient has a history of smoking or diabetes. As these guidelines are incorporated into physician practice, PAD diagnosis rates are forecasted to increase. AngioSoma President, Alex Blankenship, said, “We are extremely pleased to own this very promising technology and look forward to going forward with the United States Food and Drug Administration to authorize our innovative catheter into the market.”About AngioSoma, Inc.AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products and medical devices to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals™. Learn more at www.muscles4U.com and htttps://muscles4u.blogstop.com.  Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook.Notice Regarding Forward Looking StatementsThis news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.CONTACTAngioSoma, Inc.Alex BlankenshipAlex@AngioSoma.com(832) 781- 8521

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.